HMGN2P25: A Potential Drug Target for Cancer (G729687)

Target Name: HMGN2P25

NCBI ID: G729687

HMGN2P25

Other Name(s): high mobility group nucleosomal binding domain 2 pseudogene 25 | High mobility group nucleosomal binding domain 2 pseudogene 25

HMGN2P25: A Potential Drug Target for Cancer

High mobility group nucleosomal binding domains (HMGNs) are a family of non-coding RNA molecules that play a crucial role in the regulation of chromatin structure and gene expression. HMGNs are composed of several domains, including the core RNA molecule, a repeat domain, and a tail domain. One of the most well-studied HMGNs is HMGN2P25, which is a pseudogene located on chromosome 16p13.3.

HMGN2P25 is a 21-kDa protein that contains 119 amino acid residues. It is primarily localized to the nucleosome, where it interacts with histone proteins to regulate chromatin structure and gene expression. HMGN2P25 has been shown to play a role in the regulation of gene expression. , and is therefore considered a potential drug target.

Expression and localization

HMGN2P25 is expressed in a variety of tissues and organisms. It is expressed in liver cells, kidney cells, and embryonic stem cells, and is highly expressed in tumor cells. In addition, HMGN2P25 is located on nucleosomes in chromatin and is an intranuclear structural protein responsible for storing and transporting chromosomal DNA.

Function

HMGN2P25 is involved in chromosome assembly and stability during the cell cycle. It is expressed in G1 phase, S phase and G2 phase, and plays an important role in the phase of chromosome condensation. Loss of HMGN2P25 can lead to chromosomal instability, leading to cell cycle abnormalities and tumorigenesis.

In addition, HMGN2P25 also plays an important role in gene expression. Research shows that HMGN2P25 can bind to the DNA of certain genes, thereby affecting the transcription of these genes. It can also bind to RNA-binding proteins (RBP) to promote RNA binding and affect gene expression.

drug target

HMGN2P25 is a potential drug target because it is highly expressed in various cancers. For example, the expression level of HMGN2P25 is positively correlated with the prognosis of various cancers, including liver cancer, breast cancer, and lung cancer. Moreover, inhibition of HMGN2P25 has been shown to inhibit the progression of various cancers, including liver cancer, breast cancer, and lung cancer.

In addition, HMGN2P25 also interacts with some drugs. For example, the combination of HMGN2P25 and the anti-tumor drug epidermal growth factor (EGFR) will reduce the extracellular concentration of EGFR, thus enhancing the killing effect of EGFR on tumor cells.

in conclusion

HMGN2P25 is a protein expressed in a variety of tissues and organisms. It participates in chromosome assembly and stability during the cell cycle, and also plays an important role in gene expression. Loss of HMGN2P25 can lead to chromosomal instability, leading to cell cycle abnormalities and tumorigenesis. In addition, HMGN2P25 is a potential drug target because it is highly expressed in a variety of cancers and can be combined with a variety of drugs. Therefore, HMGN2P25 is a molecule worthy of further study and may be a potential drug target.

Protein Name: High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 25

The "HMGN2P25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN2P25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets